在被诊断为肝细胞癌后,艾滋病毒感染者和没有感染者的相对比较的5年生存期:一个多中心研究
Massimo Iavarone1,2, Eleonora Alimenti1, Massimo Puoti3,4
1Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy.
概括
患有肝细胞癌 (HCC) 的艾滋病毒 (PWH) 患者的存活率与艾滋病毒阴性患者相似,尽管瘤更为晚期. 积极的治疗策略可能会抵消HCC的PWH最初的缺点.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- 关于艾滋病毒感染者 (PWH) 肝细胞癌 (HCC) 存活率存在相互矛盾的数据.
- 瘤的攻击性和获得治愈治疗的机会是影响PWH中HCC结果的潜在因素.
- 这项研究比较了PWH和HIV阴性个体之间的HCC结果.
研究的目的:
- 根据艾滋病毒状况,比较HCC患者的临床特征,治疗准入和整体存活期 (OS).
- 确定PWH与HIV阴性患者初始治疗HCC后死亡率和复发的预测因素.
主要方法:
- 分析了2005-2023年间在四个意大利北部的第三级转诊中心诊断出HCC的606名患者.
- 使用逆概率治疗权重和倾向得分 (IPTW/PS) 方法来根据艾滋病毒状况比较结果.
- 采用考克斯回归模型来评估治疗后的死亡预测因素和复发率.
主要成果:
- 与艾滋病毒阴性患者 (n=463) 相比,PWH (n=143) 患者年轻,男性占主导地位,儿童-皮格甲肝硬化比例较低.
- 尽管监测率相似,但PWH更频繁地呈现BCLC-C阶段HCC (22%vs10%).
- 五年后的OS是可比的 (43.4%与44.1%相比),但PWH在IPTW/PS分析后显示了更高的两年复发率 (47.4%与22.8%相比).
结论:
- 艾滋病毒感染者 (PWH) 的肝细胞癌 (HCC) 存活率与艾滋病毒阴性个体相似.
- 尽管呈现出更先进的瘤,并经历了更高的复发率,PWH的结果是可比的.
- 积极的下降阶段和获得治愈治疗似乎可以抵消PWH与HCC的初始缺点.
关键词:
艾滋病 艾滋病 艾滋病是什么?艺术 艺术 艺术 艺术我们的BCLCLC是BCLCLC.在HCC中,HCC是HCC.艾滋病病毒 艾滋病病毒 艾滋病病毒艾滋病毒阴性整体存活率肝移植 肝移植 肝移植手术 手术 手术 手术 手术 手术 手术更多相关视频
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
37.0K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.4K
相关概念视频
01:21Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
01:20Comparing the Survival Analysis of Two or More Groups
541
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
541
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K